据央视新闻客户端，当地时间10月6日，瑞典卡罗琳医学院宣布，将2025年诺贝尔生理学或医学奖授予 科学家玛丽·E·布伦科（Mary E.Brunkow）、弗雷德·拉姆斯德尔（Fred Ramsdell）和坂口志文（Shimon Sakaguchi），表彰他们在外周免疫耐受方面的研究贡献，获奖者将平分1100万瑞典克朗（约合832万元 人民币）奖金。 三名获奖者"合力"解码人体免疫系统 诺奖官网公报介绍，人体强大的免疫系统必须得到调节，否则可能会攻击自身器官。三名获奖者在外周 免疫耐受方面取得了突破性发现，坂口志文发现了调节性T细胞，它可以有效阻止免疫系统攻击人体自 身，布伦科和拉姆斯德尔则找到了与之相关的基因，这些成果加深了科学界对免疫系统如何运作的理 解，推动了自身免疫性疾病等方面的研究。 据介绍，人体免疫系统的作用，是保护人体免受数千种不同微生物的入侵，微生物有不同的外观，并且 许多伪装成与人类细胞相似的形式，免疫系统如何决定它应该攻击什么，和它应该防御什么成为免疫机 制的关键。 玛丽·E·布伦科、弗雷德·拉姆斯德尔和坂口志文三位科学家确定了免疫系统的防御机制，即"调节性T细 胞"，它可以防止免疫细胞攻击 ...

Core Insights - The report highlights an increasing investment trend from both domestic and foreign investors in service-oriented companies and innovative pharmaceutical firms, particularly in the context of anticipated interest rate cuts in Q4 [1][2] - The Hang Seng Healthcare Index rose by 2.2% this week, underperforming the broader market, with CXO, biopharmaceuticals, and traditional Chinese medicine sectors showing better performance [1] Investment Insights - The upcoming ESMO conference in mid-October is expected to provide significant data releases from companies such as Kangfang Biotech, Kelun-Biotech, and Rongchang Biotech, which are recommended for close monitoring [2] - With an increase in industry catalysts starting in October, the market is anticipated to rebound, focusing on the following segments: 1. Innovative drugs: Companies like 3SBio and Eucure Biopharma have rich short-term catalysts, and their valuations do not yet reflect the value of core blockbuster products. Companies like Sinopharm and Legend Biotech are considered undervalued with clear long-term growth logic [2] 2. CXO: Leading companies in this segment are expected to benefit from high downstream demand and marginal improvements in financing conditions, such as WuXi AppTec [2]

Core Viewpoint - The Hang Seng Healthcare Index increased by 2.2% last week, underperforming the broader market, with the CXO, biopharmaceutical, and traditional Chinese medicine sectors showing better performance [1] Group 1: Market Trends - Domestic investors have been increasing their holdings through the Hong Kong Stock Connect since September, while foreign investors' holdings have slightly decreased since mid-year, although both continue to focus on innovative drug companies [1] - Both domestic and foreign investors have increased their positions in service-related stocks, particularly those that may benefit from interest rate cuts, such as CXO companies [1] Group 2: Upcoming Events - The ESMO conference is scheduled for mid to late October, and the report suggests focusing on companies like CanSino Biologics (09926), Kelun-Biotech (06990), and Rongchang Biologics (09995), which are expected to release significant data [1] Group 3: Investment Recommendations - The report recommends attention to the following sectors: 1) Innovative drugs: Companies like 3SBio (01530) and Eucure Biopharma-B (06996) have abundant short-term catalysts and their valuations do not yet reflect the value of core products; companies like Ascletis Pharma (02096), Hutchison China MediTech (00013), and Legend Biotech are significantly undervalued with clear long-term growth logic [1] 2) CXO: Leaders in this segment, such as WuXi AppTec (02268), are expected to benefit from high downstream demand and improving financing conditions [1]

Core Insights - The report from CMB International highlights the release of the first batch of innovative pharmaceutical technology medical insurance payment incentive catalog by Zhejiang Province, which is expected to alleviate the challenges of innovative drugs entering hospitals [1] - Despite the Trump administration's announcement of a 100% tariff on imported innovative drugs, the overall impact on China's pharmaceutical industry chain is considered manageable, with a recommendation to monitor subsequent developments [1] - The upcoming ESMO conference in mid to late October is noted as a key event, with a focus on companies such as CanSino Biologics (09926), Kelun-Biotech (06990), and Rongchang Biologics (688331.SH) that are expected to release significant data [1] Industry Summary - The Hong Kong pharmaceutical sector has shown relatively flat performance in September, but with increasing industry catalysts such as academic conferences and favorable policy implementations in October, a market rebound is anticipated [1] - The report recommends focusing on specific segments: 1) Innovative drugs: Companies like 3SBio (01530) and Eucure Biopharma-B (06996) have rich short-term catalysts and their valuations do not yet reflect the core value of major products; companies like Ascletis Pharma (02096), Hutchison China MediTech (00013), and Legend Biotech are considered significantly undervalued with clear long-term growth logic [1] 2) CXO: Leaders in this segment, such as WuXi AppTec (02268), are expected to benefit from high downstream demand and marginal recovery in financing [1]

Core Insights - The Hong Kong pharmaceutical market has shown a structural trend since 2025, with the innovative drug sector becoming a focal point for investment due to its transition to profitability and international expansion [1][2] Industry Overview - In the first half of 2025, 149 Hong Kong-listed pharmaceutical companies reported a 29.7% year-on-year increase in net profit attributable to shareholders, with 36 innovative drug companies generating revenues of 28.5 billion yuan, marking a 15.8% growth [1] - The innovative drug sector has transitioned from a "research and development phase" to a "commercialization phase," driven by companies like BeiGene and Innovent Biologics, which have validated their commercialization capabilities [2] - The current market sentiment favors "high cost-performance" targets, with a focus on companies that have stable R&D pipelines and mature commercialization systems [2] Investment Opportunities - The innovative drug sector is characterized by "high certainty and high elasticity," with increased market rotation and investment interest in companies with strong performance and growth potential [2][3] - Companies with differentiated innovation capabilities and global commercialization potential are recommended for investment, as they are expected to experience rapid revenue growth and profitability [3] - The market is actively seeking investment targets that combine "valuation recovery and product realization," with a focus on companies like Vison Pharma, which is positioned in the growth hormone market [4][5] Company Spotlight: Vison Pharma - Vison Pharma is recognized as an undervalued innovative drug company with both valuation recovery and growth potential, focusing on the growth hormone market [5][6] - The company's core product, Lonapegsomatropin, is expected to be commercialized in China, with significant market potential and a strong clinical validation track record [6][7] - Vison Pharma has established strategic partnerships to enhance its commercialization capabilities, including exclusive promotion agreements and local production arrangements [7][8] Market Positioning - Vison Pharma's upcoming product launch is crucial for its value realization, with the potential to capture a significant market share in the long-acting growth hormone segment [6][9] - The company is well-positioned in a "value gap" state, avoiding the risks associated with early-stage biotech while not being assigned the high valuations typical of mature pharmaceutical companies [9]

Core Viewpoint - The market is expected to enter a "low season" mode due to the impact of the National Day and Mid-Autumn Festival holidays, along with uncertainties surrounding the U.S. government's short-term financing bill and potential overseas disturbances [1] Market Conditions - There is still divergence in the market regarding the timing and extent of interest rate cuts by the Federal Reserve [1] - Some quality sectors in the Hong Kong stock market have valuations close to historical highs, leading to short-term profit-taking pressure [1] Investment Strategy - The company recommends maintaining a "high elasticity" and "high dividend" barbell strategy for industry allocation, with appropriate adjustments based on policy catalysts [1] - Selected stocks for October include: Qifu Technology, Prosperity Industrial Trust (00778), OmniVision Technologies, Kuaishou-W (01024), Alibaba-W (09988), China National Heavy Duty Truck Group (03808), CanSino Biologics (09926), Pop Mart International (09992), and China Power (02380) [1] Sector Insights - Driven by technological narratives, there is a continuous increase in domestic and international computing power investments [1] - The demand from domestic investors for quality Hong Kong stocks in the AI sector remains strong [1]

Core Insights - The article highlights the strong performance of various mutual funds in China for the year-to-date, particularly in the equity and mixed fund categories, with average returns exceeding 35.4% for ordinary stock funds and 29.1% for mixed funds [2][3]. Fund Performance - The top-performing fund is the Yongying Technology Select Fund managed by Ren Jie, with a year-to-date return of approximately 194.49% [3][4]. - The second-best fund is the Huatai Hong Kong Advantage Select Fund managed by Zhang Wei, achieving a return of over 155% [3][14]. - The third position is held by the China Europe Digital Economy Fund managed by Feng Ludan, with a return of nearly 141% [3][4]. - In the bond fund category, the Southern Changyuan Convertible Bond Fund managed by Liu Wenliang leads with a return of 44.21%, outperforming many equity funds [15]. Sector-Specific Insights - The article notes that funds focused on specific sectors, such as technology and healthcare, have shown exceptional performance, with many funds achieving returns exceeding 100% [5][6]. - The Huazhong Medical Biology Fund, managed by Sang Xiangyu, achieved a return of 103.31%, reclaiming the top position among ordinary stock funds [5][7]. - The article emphasizes that without a return of at least 110%, funds could not make it into the top twenty performers this year [2]. Index Fund Performance - In the index fund category, the top three funds are all focused on innovative pharmaceuticals, with returns exceeding 106% [10][12]. - The Wanji Zhongzheng Hong Kong Stock Connect Innovative Drug ETF, managed by He Fangzhou, leads with a return of 114.01% [12][10]. QDII Fund Insights - QDII funds have predominantly invested in Hong Kong stocks, with the top-performing fund being the Huatai Hong Kong Advantage Select Fund, achieving a return of over 155% [13][14]. - Other notable QDII funds include the Guangfa Zhongzheng Hong Kong Innovative Drug ETF and the Yifangda Global Pharmaceutical Industry Fund, both exceeding 100% returns [13][14]. Bond Fund Insights - The Southern Changyuan Convertible Bond Fund, with a return of 44.21%, showcases the strong performance of bond funds this year, attributed to their equity components [15].

Core Viewpoint - The article discusses the recent recovery of the Hong Kong stock market and its implications for the primary market, highlighting significant IPO activity and the potential for investment returns [6][25]. Group 1: Market Recovery - The Hong Kong stock market has shown a remarkable turnaround, with the Hang Seng Index rising over 20% and IPO fundraising exceeding 100 billion HKD in 2025 [6]. - From January to August 2025, 59 companies went public, marking a 37% increase compared to 2024, with total funds raised reaching approximately 134.5 billion HKD, a nearly sixfold year-on-year increase [6]. Group 2: Investment Returns - Successful IPOs have revitalized investor confidence, with cornerstone investors in companies like Yaojie Ankang achieving returns of up to 10 times their investment [10][11]. - The case of Yaojie Ankang illustrates that despite market volatility, early investors can still realize substantial gains, with cornerstone investors earning significant returns even after a drop in stock price [10]. Group 3: Implications for Fund Management - A successful IPO can provide hidden value that may offset several years of management fees for a fund, enhancing overall fund performance [13][18]. - For instance, the IPO of Ming En Biotechnology resulted in an average return of over 300% for investors, with some achieving returns exceeding 600% [14][15]. Group 4: Importance of Exits - The article emphasizes that continuous profitability and successful exits are crucial for maintaining investor trust and securing future fundraising [20][25]. - The case of Yushu Technology demonstrates how a single successful investment can significantly impact a fund's overall performance, with potential valuations reaching up to 1 billion HKD [22][23].

康方生物科技(開曼)有限公司 Akeso, Inc. (於開曼群島註冊成立的有限公司) (Incorporated in the Cayman Islands with limited liability) Stock Code 股份代號 : 9926 2025 中期報告 INTERIM REPORT 康方生物科技(開曼)有限公司 Akeso, Inc. INTERIM REPORT 2025 中期報告 目 錄 | | 頁次 | | --- | --- | | 公司簡介 | 2 | | 釋義 | 3 | | 公司資料 | 6 | | 摘要 | 8 | | 管理層討論及分析 | 9 | | 補充資料 | 27 | | 獨立審閱報告 | 66 | | 中期簡明綜合損益及其他全面收益表 | 67 | | 中期簡明綜合財務狀況表 | 69 | | 中期簡明綜合權益變動表 | 71 | | 中期簡明綜合現金流量表 | 73 | | 中期簡明綜合財務資料附註 | 75 | 公司簡介 康方生物科技（開曼）有限公司是一家致力於研究、開發、生產及商業化讓全球病人可負擔的創新抗體藥的生物製藥 公司。自成立以來，本公司建立了端對端 ...

Core Viewpoint - The Hong Kong stock market, particularly the technology sector, is experiencing a rebound driven by advancements in AI and positive market sentiment, with significant capital inflows into technology-focused ETFs [1] Group 1: Market Performance - On September 30, the Hang Seng Index opened up by 0.19% and the Hang Seng Tech Index rose by 0.34% [1] - The Hong Kong Stock Connect Technology ETF (159101) saw a slight increase in early trading, with notable gains in stocks such as Hua Hong Semiconductor, UBTECH, Kangfang Bio, Sunny Optical Technology, and Bilibili [1] - As of September 29, the Hong Kong Stock Connect Technology ETF (159101) recorded a net capital inflow of 436 million yuan over the past 10 trading days, indicating strong investor interest [1] Group 2: Sector Analysis - Huatai Securities reports that the rapid rebound of Hong Kong tech stocks is attributed to accelerated domestic AI developments [1] - The technology sector is expected to lead a third revaluation of the Hong Kong market, as negative factors like the food delivery competition are largely priced in, while AI models, chip procurement, and capital expenditures are anticipated to accelerate [1] - With the onset of a new round of monetary easing by the Federal Reserve and advancements in the internet and technology sectors, market sentiment in Hong Kong may continue to improve, suggesting that the technology sector remains a favorable area for investment [1] Group 3: ETF Composition - The Hong Kong Stock Connect Technology ETF (159101) closely tracks the Guotai Hong Kong Stock Connect Technology Index, selecting 30 large-cap stocks with high R&D investment [1] - The top ten weighted stocks account for over 75% of the ETF, including major internet giants like Tencent and Alibaba, as well as emerging players like Li Auto and BeiGene, covering popular sectors such as "software and hardware + new consumption + innovative pharmaceuticals + new energy vehicles" [1]